HIF1A and cancer: Additionally, recent work at the NCI suggests that prolonged Topo 1 inhibition can mediate a novel Topo 1-dependent hypoxia-inducible factor 1 alpha (HIF-1α) inhibition mechanism [17], another promising cancer drug target that has been the subject of intense research and screening efforts.